Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy-Reference-Cited by-同舟云学术

Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy

Published:2014-12 Issue:1-2 Volume:277 Page:6-12
ISSN:0165-5728
Container-title:Journal of Neuroimmunology
language:en
Short-container-title:Journal of Neuroimmunology

Author:

Serana Federico,Chiarini Marco,Sottini Alessandra,Bertoli Diego,Giustini Viviana,Vaglio Tessitore Marion,Caimi Luigi,Capra Ruggero,Imberti Luisa^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,Immunology,Immunology and Allergy

Reference66 articles.

1. Value of MRI as a surrogate marker for PML in natalizumab long-term therapy;Ayzenberg;J. Neurol.,2012

2. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section;Berger;Neurology,2013

3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy;Bloomgren;N. Engl. J. Med.,2012

4. Next generation sequencing for TCR repertoire profiling: platform-specific features and correction algorithms;Bolotin;Eur. J. Immunol.,2012

5. Neonatal screening for severe primary immunodeficiency diseases using high-throughput triplex real-time PCR;Borte;Blood,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?;PLOS ONE;2017-04-13

2. Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation;PLOS ONE;2016-08-03

3. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies;Journal of Neuroinflammation;2016-06-27

4. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA’s adverse event reporting system;Expert Opinion on Drug Safety;2016-06-20

5. Personalized Medicine and Theranostics;Translational Neuroimmunology in Multiple Sclerosis;2016